Download our BMT Q4 Outlook infographic today
Find out about top-line trial data, approval decisions, advisory panel meetings and more in advance of others. The outcomes of these events dramatically impact the competitive landscape of late-stage drug development and impact the stock prices of many market players, especially smaller companies. Therefore, the sooner you know about them, the better.
Discover the 10-20 most important expected pharma and biotech events in the coming 3 months and you will be able to predict the future pharma landscape.
Biomedtracker is the leader in providing objective information alongside evidence-based clinical assessments and investment research on pipeline drugs worldwide.
Discover the catalysts from 23 drugs, devices and diagnostics expected to occur in Q4 2016. Learn each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group.
